Literature DB >> 3928010

Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.

J P Finberg, M B Youdim.   

Abstract

The selective monoamine oxidase (MAO) inhibitors clorgyline, selegiline and AGN 1135 did not cause a change in responses of the cat nictitating membrane to preganglionic sympathetic nerve stimulation at 5 Hz. Both selective MAO-A and MAO-B inhibitors markedly potentiated nictitating membrane contractions in response to beta-phenylethylamine (PEA). However, the responses to tyramine were unchanged. The pressor responses to tyramine were potentiated by the selective MAO-A inhibitor clorgyline (2 mg kg-1) but not by selegiline (1.0 mg kg-1) and AGN 1135 (1.5 mg kg-1), selective MAO-B inhibitors. At the doses used selegiline and AGN 1135 caused a near total selective inhibition of liver and brain MAO-B, while clorgyline inhibited MAO-A only in the brain. AGN 1135, like selegiline, could be a useful drug in potentiating the action of L-DOPA in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928010      PMCID: PMC1916611          DOI: 10.1111/j.1476-5381.1985.tb08891.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Monoamine oxidase in rat arteries: evidence for different forms and selective localization.

Authors:  J F Coquil; C Goridis; G Mack; N H Neff
Journal:  Br J Pharmacol       Date:  1973-08       Impact factor: 8.739

2.  Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species.

Authors:  R F Squires
Journal:  Adv Biochem Psychopharmacol       Date:  1972

3.  Some puzzling pharmacological effects of monoamine oxidase inhibitors.

Authors:  J Knoll; K Magyar
Journal:  Adv Biochem Psychopharmacol       Date:  1972

4.  Occurrence and properties of monoamine oxidase in adrenergic neurons.

Authors:  B Jarrott
Journal:  J Neurochem       Date:  1971-01       Impact factor: 5.372

5.  Evidence that deprenyl, A type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine.

Authors:  L L Simpson
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

6.  Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.

Authors:  J D Elsworth; V Glover; G P Reynolds; M Sandler; A J Lees; P Phuapradit; K M Shaw; G M Stern; P Kumar
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

7.  Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.

Authors:  A R Green; M B Youdim
Journal:  Br J Pharmacol       Date:  1975-11       Impact factor: 8.739

8.  Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl.

Authors:  V Glover; C J Pycock; M Sandler
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

9.  Varicose veins in tropical Africa.

Authors:  J B Richardson; M Dixon
Journal:  Lancet       Date:  1977-04-09       Impact factor: 79.321

10.  Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

Authors:  W Birkmayer; P Riederer; L Ambrozi; M B Youdim
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

View more
  12 in total

1.  Pressor response to oral tyramine and monoamine oxidase inhibition during treatment with ralfinamide (NW-1029).

Authors:  Andrea F D Di Stefano; Milko Massimiliano Radicioni; Antonio Rusca
Journal:  Neurotox Res       Date:  2012-08-08       Impact factor: 3.911

2.  Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.

Authors:  M B Youdim; A Gross; J P Finberg
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 3.  The discovery and development of rasagiline as a new anti-Parkinson medication.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2020-01-23       Impact factor: 3.575

4.  Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers.

Authors:  Andrea Francesco Daniele Di Stefano; Antonio Rusca
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-08-19       Impact factor: 3.000

Review 5.  Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

Authors:  M B Youdim; M Weinstock
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

Review 6.  The role of rasagiline in the treatment of Parkinson's disease.

Authors:  Julie Leegwater-Kim; Elena Bortan
Journal:  Clin Interv Aging       Date:  2010-05-25       Impact factor: 4.458

Review 7.  Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.

Authors:  M B Youdim; P Riederer
Journal:  J Neural Transm Gen Sect       Date:  1993

8.  Spotlight on rasagiline in Parkinson's disease.

Authors:  Vicki Oldfield; Gillian M Keating; Caroline M Perry
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.

Authors:  Orly Weinreb; Tamar Amit; Yotam Sagi; Noam Drigues; Moussa B H Youdim
Journal:  J Neural Transm (Vienna)       Date:  2009-04-25       Impact factor: 3.575

Review 10.  Rasagiline: a review of its use in the management of Parkinson's disease.

Authors:  Vicki Oldfield; Gillian M Keating; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.